BioNTech (NASDAQ:BNTX) CEO Sells $3,280,660.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 34,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00. Following the completion of the transaction, the chief executive officer owned 568,209 shares of the company’s stock, valued at $54,826,486.41. This represents a 5.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Stock Performance

Shares of NASDAQ:BNTX traded down $0.86 on Wednesday, hitting $95.83. 407,411 shares of the company were exchanged, compared to its average volume of 1,104,336. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The stock’s 50 day moving average price is $97.13 and its 200 day moving average price is $95.10. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $24.23 billion, a P/E ratio of -12.24 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech’s revenue was down 59.5% on a year-over-year basis. During the same period in the previous year, the company earned ($1.60) earnings per share. Sell-side analysts predict that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on BNTX. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Berenberg Bank set a $140.00 price target on shares of BioNTech in a report on Wednesday. Morgan Stanley reduced their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. UBS Group restated a “buy” rating on shares of BioNTech in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Institutional Trading of BioNTech

A number of hedge funds have recently modified their holdings of the stock. Flossbach Von Storch SE purchased a new stake in shares of BioNTech in the second quarter valued at approximately $207,142,000. BNP Paribas Financial Markets lifted its position in shares of BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after buying an additional 474,796 shares in the last quarter. First Trust Advisors LP grew its stake in BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after acquiring an additional 451,124 shares during the period. Assenagon Asset Management S.A. acquired a new stake in BioNTech in the 2nd quarter valued at $39,385,000. Finally, SEB Asset Management AB purchased a new stake in BioNTech in the 1st quarter worth $17,804,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.